TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Chinese Response Style Questionnaire-short Form Revised (CRSQ-10)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Number of needle routing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Epidural catheter placement time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Rate of patients with CR at first restaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PFS rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dry Eye Questionnaire 5 (DEQ-5) Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Recovery of motor function after stroke
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Treatment for clinically suspected or culture-proven UTI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Adherence to HIV treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perceived dyspnea intensity
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: neural correlates of face/voice interaction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: neural correlates of face/voice respective contribution
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change from baseline in blood pressure (BP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from baseline in pulse rate (PR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Occurence of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Treatment success based on Amsel criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients who have undergone lumbar instrumented arthrodesis procedures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Protective level of anti HBs antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Function and disability outcomes
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Evaluation of clinical scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse reactions and events
Endpoint domain: Adverse events/effects
Primary endpoint: Composite overall response rate (CORR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Freedom from Procedure-Related Infection
Endpoint domain: Adverse events/effects
Primary endpoint: Haematoma growth
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Radiation Dose to the Heart
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Radiation Dose to the Lung
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Area Under the Curve (AUC0-12hrs) of Plasma BH4 Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Numeric Pain Rating (NPR) or patient estimation of improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Target to Background Ratio (TBR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of CO2 Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Cholesterol Esterification Deficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants With Spur Cell Anemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Participant Transplant-Free Survival
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of Change in WOMAC Pain Subscale Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Episodes of Clinically-diagnosed Acute Otitis Media
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percentage of change in children receiving treatment for pneumonia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percentage of change in children receiving treatment for diarrhea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percentage of change in children receiving treatment for fever
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: CV risk associated with DNA characteristics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Gene sequence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of ACL injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Hemodynamic tolerance defined by stable mean blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: amplitude of motor evoked potentials
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Hopkins Verbal Learning Test (HVLT) Total Recall
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Mean difference in flare
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: proportion of subjects with HBV DNA < 300 copies/ml
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Alterations in blood glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Degree of foveal elongation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severe late complications rate
Endpoint domain: Adverse events/effects
Primary endpoint: Diagnosis of HCV related hepatocellular carcinoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Proportion of patients who discontinued therapy with Osimertinib
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Proportion of patients with xerostomia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of recurrent venous thromboembolism
Endpoint domain: Adverse events/effects
Primary endpoint: Toxicant Exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Uptake of [18F]-FMISO and observation of hypoxic tumors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in Corneal staining score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence/absence of complications
Endpoint domain: Adverse events/effects
Primary endpoint: Numbers of anomalies in the processing of movement-execution
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Participants who Experienced Dose-Limiting Toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: ISR in Response to a Glucose Clamp
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: C-peptide Concentration in Response to a Glucose Clamp
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Insulin Concentration in Response to a Glucose Clamp
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Number of PDA Closures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of Vasopressor Use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the receiver operating curve (ROC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Depressive symptoms on Edinburgh Postpartum Depression scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Depressive symptoms on Patient Health Questionnaire-9 (PHQ-9)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of Participants With Prostate Cancer Progression
Endpoint domain: Mortality/survival
Primary endpoint: Graft and Patient Survival
Endpoint domain: Mortality/survival
Primary endpoint: EXIT-25
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: 3 year local control rate
Endpoint domain: Mortality/survival
Primary endpoint: Clinical appearance of the lichen lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Adverse event number and severity
Endpoint domain: Adverse events/effects
Primary endpoint: Prevalence of human papillomavirus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Medication tolerability and safety
Endpoint domain: Adverse events/effects
Primary endpoint: Diarrhea Duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in Cardiovascular Disease Risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of Participants Reporting Solicited Local or Systemic Reactions Post-Dose 5 of DAPTACEL® Vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Anti-Pertussis 4-Fold Rises Post-Dose 5 of DAPTACEL® Vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geometric Mean Titers (GMTs) of Anti-Pertussis, Anti-Diphtheria, and Anti-Tetanus Toxoids Pre- and Post-dose 5 of DAPTACEL® Vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Postural Alignment - Neck Position
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postural Alignment - Trunk Position
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postural Alignment - Hip/Knee Position
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of inflammatory changes within the tumor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Nature of the agent
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Opioid consumption 24 hours postoperatively
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Duration of drains
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in infrared thermography of cold hypersensitivity on hands
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in Disability of the Arm, Shoulder and Hand (DASH) questionnaire at 8 weeks
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change from Baseline in Disability of the Arm, Shoulder and Hand (DASH) questionnaire at 16 weeks
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: spherical equivalent refraction (SER) change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence rate to CPAP treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ratio of patients with compliance with the treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Arterial dilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in math test scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in reading test scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Edmonton Symptom Assessment System
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Resolution of refractory convulsive status epilepticus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Participants With Graft Survival at 12 Months
Endpoint domain: Mortality/survival
Primary endpoint: Either Equivalent or Improved Estimated Glomerular Filtration Rate (eGFR) at One Year in the Rapamycin Group
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Improved Histology at 12 Months in the Rapamycin Group
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Best operating characteristics (sensitivity and specificity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of Periodontitis stage III & IV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Greater Than 100 Nmol/L 25(OH)D
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Radiation Dose during Procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alzheimer's Disease Assessment Scale, Cognitive Subscale (ADAS-Cog)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Evolution of retina diseases
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mitoferrin-1 expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Elbow Flexion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measurements of Distance Between Breast Area Reference Points
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GvHD-markers on endomicroscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: urine GRP levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: infant pulmonary function tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percentage of Participants Transitioned to LEM
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adequacy of cervical dilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Esophageal pressures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Prevalence of Positive Poly-specific Enzyme Immunoassay (EIA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change from baseline FEV1%predicted
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in Mean Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Accuracy of treatment planning using MRI scans
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of dose delivery using MRI scans
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response to antiplatelet therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: HPV-vaccine-dose Receipt
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Virologic Success (HIV-1 RNA < 50 Copies/mL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Colony forming units of Streptococcus mutans, Lactobacilli spp. and Actinomyces species
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: treatment outcomes for patients with SDS and SDS-Like conditions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in CD8+ T Cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Occurrence of major post-operative complications
Endpoint domain: Adverse events/effects
Primary endpoint: Contact Lens High Contrast Visual Acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Distinction between 'dry' and 'wet' clinical state in ADHF patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Observed clinical outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rocuronium efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Liver fibrosis progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Uncarboxylated MGP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Uncarboxylated osteocalcin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: lumen stenosis rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: plaque stability prediction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: plaque detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Neutralising capacity of naturally produced antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Subjective xerostomia
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Frequency of de novo mutations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Systematic assessment of underlying genetic makeup of LCH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Difference in LCH-related somatic mutations by race/ethnicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Frequency of depressive and hypomanic episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of depressive and hypomanic episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of depressive and hypomanic episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of apolipoprotein E (apo-E) allele
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence to preventative medication use
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Adherence to reliever medication use
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Pattern of myocarditis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Communication and Symbolic Behavior Scales (CSBS) Score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Autism Diagnostic Observation Schedule (ADOS) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mullen Scales of Early Learning (MSEL) Score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Vineland Adaptive Behavior Scales, Second Edition (Vineland II) Score
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: NEO-FFI score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Psychomotor Function Using Speed and Coordination on the CogScreen Pathfinder Number (PFN) Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: WOMAC questionnaire scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: t1/2 (terminal half-life of the analyte in plasma)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC (area under the concentration-time curve of the analyte in plasma)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Surviving 100 days post-transplant
Endpoint domain: Mortality/survival
Primary endpoint: Median Time from Placement of Foley Catheter to Vaginal Delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Nutrition Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Maximum concentration (Cmax) of estetrol in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of drospirenone in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration versus time curve from time 0 to the last determined concentration (AUC0-tdlc) of estetrol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Viral load of HCV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: brain inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Real life falls
Endpoint domain: Adverse events/effects
Primary endpoint: Positive Mood Effects
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: sural Nerve Conduction Velocity (NCV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Overall Fit Acceptance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall Stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: System set-up time
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Maximum Tolerated Dose (MTD or Recommended Phase 2 Dose (RP2D)
Endpoint domain: Adverse events/effects
Primary endpoint: Early detection of PRDVT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Number of participants with adverse events at Week 12
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with adverse events through study completion
Endpoint domain: Adverse events/effects